Santoro, A.; Travaglino, A.; Inzani, F.; Straccia, P.; Arciuolo, D.; Valente, M.; D’Alessandris, N.; Scaglione, G.; Angelico, G.; Piermattei, A.;
et al. Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis. Diagnostics 2022, 12, 633.
https://doi.org/10.3390/diagnostics12030633
AMA Style
Santoro A, Travaglino A, Inzani F, Straccia P, Arciuolo D, Valente M, D’Alessandris N, Scaglione G, Angelico G, Piermattei A,
et al. Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis. Diagnostics. 2022; 12(3):633.
https://doi.org/10.3390/diagnostics12030633
Chicago/Turabian Style
Santoro, Angela, Antonio Travaglino, Frediano Inzani, Patrizia Straccia, Damiano Arciuolo, Michele Valente, Nicoletta D’Alessandris, Giulia Scaglione, Giuseppe Angelico, Alessia Piermattei,
and et al. 2022. "Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis" Diagnostics 12, no. 3: 633.
https://doi.org/10.3390/diagnostics12030633
APA Style
Santoro, A., Travaglino, A., Inzani, F., Straccia, P., Arciuolo, D., Valente, M., D’Alessandris, N., Scaglione, G., Angelico, G., Piermattei, A., Cianfrini, F., Raffone, A., & Zannoni, G. F.
(2022). Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis. Diagnostics, 12(3), 633.
https://doi.org/10.3390/diagnostics12030633